SCHEMBL1638800

SCHEMBL1638800

O=C(NN=Cc1c(O)ccc2ccccc12)c1sc2cc(F)ccc2c1Cl

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OGG1 O15527 1/20 0.59
RRM1 P23921 5/20 0.56
MEN1 O00255 8/20 0.55
KMT2A Q03164 8/20 0.55
NPC1 O15118 3/20 0.55
PAX8 Q06710 1/20 0.53
KDM4E B2RXH2 3/20 0.53
LMNA P02545 3/20 0.53
MAPT P10636 3/20 0.53
HTT P42858 2/20 0.53
HSP90AA1 P07900 2/20 0.53
GAA P10253 1/20 0.53
HPGD P15428 1/20 0.53
ALOX12 P18054 1/20 0.53
PTBP1 P26599 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
HCRTR1 O43613 2/20 0.52
NPSR1 Q6W5P4 2/20 0.52
RAB9A P51151 3/20 0.51
IDO1 P14902 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12767386 1.00 OGG1 (0.59) OGG1RRM1MEN1KMT2ANPC1
SCHEMBL1639071 1.00 OGG1 (0.59) OGG1RRM1MEN1KMT2ANPC1
SCHEMBL13971450 0.88 OGG1 (0.56) OGG1MEN1KMT2ANPC1KDM4E
SCHEMBL18479795 0.75 OGG1 (1.00) OGG1MEN1KMT2ANPC1KDM4E
SCHEMBL16035633 0.74 MEN1 (0.81) RRM1MEN1KMT2ANPC1PAX8
SCHEMBL14906922 0.74 MEN1 (0.81) RRM1MEN1KMT2ANPC1PAX8
SCHEMBL683715 0.74 MEN1 (0.85) RRM1MEN1KMT2ANPC1PAX8
SCHEMBL2847708 0.74 MEN1 (0.85) RRM1MEN1KMT2ANPC1PAX8
SCHEMBL21211326 0.73 MEN1 (0.75) RRM1MEN1KMT2ANPC1PAX8
SCHEMBL12387983 0.73 MEN1 (0.75) RRM1MEN1KMT2ANPC1PAX8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS ACUMEN PHARMACEUTICALS, INC. (US) 2011-04-28 US claimed
EP-2194975-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-ß DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUNDS Acumen Pharmaceuticals, Inc. (US) 2010-06-16 EP claimed
WO-2009009768-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUDS ACUMEN PHARMACEUTICALS, INC. (US) 2009-01-15 WO claimed
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS ACUMEN PHARMACEUTICALS, INC. (US) 2011-04-28 US disclosed
EP-2194975-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-ß DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUNDS Acumen Pharmaceuticals, Inc. (US) 2010-06-16 EP disclosed
WO-2009009768-A2 METHODS OF INHIBITING THE FORMATION OF AMYLOID-β DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUDS ACUMEN PHARMACEUTICALS, INC. (US) 2009-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098309-A1 METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS APP, APBA1, BACE1 OGG1 2777/4885RRM1 3099/4885MEN1 2974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.